← Back to Screener
Acrivon Therapeutics, Inc. Common Stock (ACRV)
Price$1.43
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-47.33%
Price vs S&P 500 (4W)-27.77%
VGM Score47.93
Market Capitalization$61.21M
All Metrics
Book Value / Share (Quarterly)$2.47
P/TBV (Annual)0.50x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.71
Price vs S&P 500 (YTD)-48.82%
EPS (TTM)$-2.00
10-Day Avg Trading Volume0.43M
EPS Excl Extra (TTM)$-2.00
EPS (Annual)$-2.02
ROI (Annual)-69.24%
Cash / Share (Quarterly)$2.52
ROA (Last FY)-60.06%
EBITD / Share (TTM)$-2.10
ROE (5Y Avg)-39.87%
Cash Flow / Share (Annual)$-2.06
P/B Ratio0.64x
P/B Ratio (Quarterly)0.56x
Net Income / Employee (Annual)$-1,052,800
Net Interest Coverage (TTM)-1.53x
ROA (TTM)-57.08%
EPS Incl Extra (Annual)$-2.02
Current Ratio (Annual)7.69x
Quick Ratio (Quarterly)8.84x
3-Month Avg Trading Volume0.73M
52-Week Price Return14.40%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$6.25
52-Week High$3.56
EPS Excl Extra (Annual)$-2.02
CapEx CAGR (5Y)142.26%
26-Week Price Return-39.41%
Quick Ratio (Annual)7.57x
13-Week Price Return-10.63%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.98x
Enterprise Value$27.14M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$3.75
3-Month Return Std Dev71.05%
Net Income / Employee (TTM)$-1,044,100
ROE (Last FY)-69.24%
EPS Basic Excl Extra (Annual)$-2.02
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.00
ROI (TTM)-64.43%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$7.78
Price vs S&P 500 (52W)-9.97%
Year-to-Date Return-40.66%
5-Day Price Return-8.33%
EPS Normalized (Annual)$-2.02
ROA (5Y Avg)-35.43%
Month-to-Date Return-10.63%
Cash Flow / Share (TTM)$-2.25
EBITD / Share (Annual)$-2.15
ROI (5Y Avg)-39.87%
EPS Basic Excl Extra (TTM)$-2.00
P/TBV (Quarterly)0.62x
P/B Ratio (Annual)0.68x
Book Value / Share (Annual)$3.56
Price vs S&P 500 (13W)-18.88%
Beta1.95x
Revenue / Share (TTM)$0.00
ROE (TTM)-64.43%
52-Week Low$1.15
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.49est. -0.54
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.13
4.13
4.13
4.21
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ACRVAcrivon Therapeutics, Inc. Common Stock | — | — | C | $1.43 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing targeted oncology medicines paired with a proprietary proteomics platform designed to identify patients most likely to respond to treatment. Its lead program, prexasertib (ACR-368), is in Phase 2 development. The preclinical pipeline targets DNA damage response and cell cycle regulation pathways.